You are in: eMedicine Specialties > Sports Medicine > Knee Knee Osteochondritis DissecansArticle Last Updated: Jul 28, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Brian Jacobs, MD, FACSM, Clinical Assistant Professor, Indiana University School of Medicine; Consulting Staff, Private Practice, Family Medicine of South Bend Brian Jacobs is a member of the following medical societies: American Academy of Family Physicians, American College of Sports Medicine, and American Medical Society for Sports Medicine Coauthor(s): Janos P Ertl, MD, Clinical Assistant Professor, Department of Orthopedic Surgery, Chief of Orthopedic Trauma, University of California at Davis; Director of Amputee Clinic, Kaiser Hospital; Gyorgy Kovacs, MD, Department of Orthopedic Surgery, Consulting Surgeon, GOC Clinic; Julie A Jacobs, PA-C, Department of Emergency Medicine, EPMG at Lakeland Hospital, Saint Joseph and Niles, Michigan Editors: Leslie Milne, MD, Department of Emergency Medicine, Assistant Clinical Instructor, Harvard University School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Russell D White, MD, Professor of Medicine, Department of Community and Family Medicine, University of Missouri-Kansas City School of Medicine, Truman Medical Center Lakewood; Jon Whitehurst, MD, Consulting Staff, Rockford Orthopedic Associates; Wylie D Lowery, Jr, MD, Department of Orthopedic Surgery, Associate Professor, George Washington University Author and Editor Disclosure Synonyms and related keywords: intra-articular osteochondrosis, OCD, osteochondral fracture, articular osteochondrosis, intra-articular segmental osteonecrosis, ossification disorder, knee injury, loose body formation, knee loose body, disordered enchondral ossification, subchondral avascular necrosis INTRODUCTIONBackgroundOsteochondritis dissecans (OCD), by definition, is a disorder of one or more ossification centers, characterized by sequential degeneration or aseptic necrosis and recalcification. OCD lesions involve both bone and cartilage. These lesions differ from acute traumatic osteochondral fractures; however, they may manifest in a similar fashion. OCD lesions also must be differentiated from meniscal pathology. OCD causes 50% of loose bodies in the knee. The etiology of these lesions is multifactorial, including trauma, ischemia, abnormal ossification centers, genetic predisposition, or some combination of these factors. Little agreement exists among researchers regarding the etiology of OCD. FrequencyUnited States
InternationalIn Sweden, prevalence is reported at the following levels:
Functional AnatomyIn skeletally immature individuals, the vascularity to epiphyseal bone is very good, supporting both osteogenesis and chondrogenesis. With disruption of the epiphyseal vessels, varying degrees and depth of necrosis occur, resulting in a cessation of growth to both osteocytes and chondrocytes. In turn, this pattern leads to nonspecific changes that produce disordered enchondral ossification, resulting in subchondral avascular necrosis or OCD. Sport Specific BiomechanicsA proposed cause of OCD is an anatomic variation allowing the lateral aspect of the femoral condyle to abut the tibial spine, leading to repetitive localized epiphyseal microtrauma with osteochondral separation and subsequent OCD. This pattern may lead the patient to walk with the tibia externally rotated to avoid this abutment. CLINICALHistory
Physical
Causes
DIFFERENTIALSMeniscus Injuries
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Acetaminophen and Codeine (Tylenol #3) |
|---|---|
| Description | Indicated for the treatment of mild to moderate pain. Use for postoperative pain control. |
| Adult Dose | 30-60 mg/dose based on codeine PO q 3-6 h; not to exceed 12 tabs/24 h |
| Pediatric Dose | 0.5-1 mg/kg/dose based on codeine q4-6h; 10-15 mg/kg/dose based on acetaminophen content PO; not to exceed 2.6 g/d of acetaminophen |
| Contraindications | Documented hypersensitivity |
| Interactions | Toxicity of codeine increases with CNS depressants, TCAs, MAOIs, neuromuscular blockers, CNS depressants, phenothiazines, and narcotic analgesics; rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity of acetaminophen |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in patients dependent on opiates because this substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction; hepatotoxicity with acetaminophen is possible following various dose levels in persons with chronic alcoholism; severe or recurrent pain or high or continued fever may indicate a serious illness; acetaminophen is contained in many OTC products, and combined use with these products may result in cumulative doses that exceed recommended maximum dose |
| Drug Name | Hydrocodone and acetaminophen (Vicodin, Lorcet-HD, Norcet) |
|---|---|
| Description | Drug combination indicated for moderate to severe pain. |
| Adult Dose | 1-2 tab or cap PO q4-6h prn pain |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d acetaminophen >12 years: 750 mg acetaminophen PO q4h; not to exceed 10 mg hydrocodone bitartrate per dose or 5 doses/24 h |
| Contraindications | Documented hypersensitivity; high-altitude cerebral edema or elevated intracranial pressure |
| Interactions | Coadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or TCAs |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Tab contains metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates because this substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction |
Have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms also may exist, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell membrane functions.
| Drug Name | Ibuprofen (Motrin, Ibuprin) |
|---|---|
| Description | DOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. |
| Adult Dose | 400-800 mg PO tid with food |
| Pediatric Dose | 10 mg/kg PO tid with food |
| Contraindications | Documented hypersensitivity; peptic ulcer disease, recent GI bleeding or perforation, renal insufficiency, or high risk of bleeding |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Naproxen (Naprosyn, Anaprox, Naprelan, Aleve) |
|---|---|
| Description | For relief of mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which results in a decrease of prostaglandin synthesis. |
| Adult Dose | 500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
| Drug Name | Ketoprofen (Oruvail, Actron, Orudis) |
|---|---|
| Description | For relief of mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which results in a decrease of prostaglandin synthesis. |
| Adult Dose | 500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
Return to play is allowed once the OCD lesion has healed and quadriceps strength has returned to within normal limits. If the athlete was treated surgically, he or she may return to play when the OCD lesion has healed and any obstructive retained hardware has been removed.
A nonunion of the OCD fragment may occur and progress to dissociation, leading to intra-articular loose body symptoms. This, in turn, may lead to a type of reconstructive procedure such as OATS or ACI (see Surgical Intervention in Acute Phase). Regardless of treatment, degenerative articular changes may develop over time.
The general rule for the prognosis of OCD is the younger the patient, the better the prognosis. The prognosis also depends on the size and severity of the lesion.
| Media file 1: Anteroposterior and lateral radiographs of medial femoral condyle osteochondritis dissecans. | |
![]() | View Full Size Image | Media type: X-RAY |
| Media file 2: Anteroposterior MRI of medial femoral condyle osteochondritis dissecans. | |
![]() | View Full Size Image | Media type: X-RAY |
| Media file 3: Lateral MRI of osteochondritis dissecans. | |
![]() | View Full Size Image | Media type: X-RAY |
| Media file 4: Herbert screw stabilization of medial femoral condyle osteochondritis dissecans. | |
![]() | View Full Size Image | Media type: X-RAY |
| Media file 5: Anteroposterior radiograph of medial femoral condyle osteochondritis dissecans. | |
![]() | View Full Size Image | Media type: X-RAY |
| Media file 6: Lateral radiograph of osteochondritis dissecans. | |
![]() | View Full Size Image | Media type: X-RAY |
| Media file 7: Arthroscopic view of medial femoral condyle osteochondritis dissecans, hinged medially. Note the large size and thickness of the fragment. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 8: Anteroposterior MRI of medial femoral condyle osteochondritis dissecans, hinged medially. | |
![]() | View Full Size Image | Media type: X-RAY |
| Media file 9: Arthroscopic view of osteochondritis dissecans of the medial femoral condyle. The osteochondral fragment has been elevated from the crater. Note the sclerotic crater with an interposed fibrocartilaginous layer. This lesion has been previously treated with drilling; an old drill hole can be seen faintly at the upper aspect of the crater. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 10: Arthroscopic debridement of the osteochondritis dissecans bed to bleeding bone. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 11: Replacement of the fragment and temporary Kirschner wire stabilization. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 12: Completed osteochondritis dissecans stabilization with 2 Herbert screws. On initial examination, the most lateral defect was comminuted and removed; the larger weight-bearing surface was maintained and stabilized. | |
![]() | View Full Size Image | Media type: Photo |
Knee Osteochondritis Dissecans excerpt
Article Last Updated: Jul 28, 2006